Clinical development of SpikoGen®, an Advax-CpG55.2 adjuvanted recombinant spike protein vaccine
Open Access
- 5 June 2024
- journal article
- review article
- Published by Taylor & Francis in Human Vaccines & Immunotherapeutics
- Vol. 20 (1) , 2363016
Abstract
Recombinant protein vaccines represent a well-established, reliable and safe approach for pandemic vaccination. SpikoGen® is a recombinant spike protein trimer manufactured in insect cells and formulated with Advax-CpG55.2 adjuvant. In murine, hamster, ferret and non-human primate studies, SpikoGen® consistently provided protection against a range of SARS-CoV-2 variants. A pivotal Phase 3 placebo-controlled efficacy trial involving 16,876 participants confirmed the ability of SpikoGen® to prevent infection and severe disease caused by the virulent Delta strain. SpikoGen® subsequently received a marketing authorization from the Iranian FDA in early October 2021 for prevention of COVID-19 in adults. Following a successful pediatric study, its approval was extended to children 5 years and older. Eight million doses of SpikoGen® have been delivered, and a next-generation booster version is currently in development. This highlights the benefits of adjuvanted protein-based approaches which should not overlook when vaccine platforms are being selected for future pandemics.Keywords
Funding Information
- National Institute of Allergy and Infectious Diseases, National Institutes of Health (5U01AI061142]; [HHS272200800039C], [HHS-N272201400053C], [HHSN272201800044C], [HHSN272201800024C)
This publication has 83 references indexed in Scilit:
- Hepatitis B vaccines: WHO position paper, July 2017 – RecommendationsVaccine, 2019
- Development of a SARS Coronavirus Vaccine from Recombinant Spike Protein Plus Delta Inulin Adjuvant2016
- Advax™, a novel microcrystalline polysaccharide particle engineered from delta inulin, provides robust adjuvant potency together with tolerability and safetyVaccine, 2015
- Severe Acute Respiratory Syndrome-Associated Coronavirus Vaccines Formulated with Delta Inulin Adjuvants Provide Enhanced Protection while Ameliorating Lung Eosinophilic ImmunopathologyJournal of Virology, 2015
- An Inactivated Cell Culture Japanese Encephalitis Vaccine (JE-ADVAX) Formulated with Delta Inulin Adjuvant Provides Robust Heterologous Protection against West Nile Encephalitis via Cross-Protective Memory B Cells and Neutralizing AntibodyJournal of Virology, 2013
- Safety and Immunogenicity of an AS01-adjuvanted Varicella-zoster Virus Subunit Candidate Vaccine Against Herpes Zoster in Adults >=50 Years of AgeThe Journal of Infectious Diseases, 2013
- CD8+ T cell efficacy in vaccination and diseaseNature Medicine, 2008
- Pathology and Pathogenesis of Severe Acute Respiratory SyndromeThe American Journal of Pathology, 2007
- Inulin‐derived adjuvants efficiently promote both Th1 and Th2 immune responsesImmunology & Cell Biology, 2004
- Vaccine adjuvants: Current state and future trendsImmunology & Cell Biology, 2004